Lee's Pharmaceutical Factory (00950): Application for clinical trial of recombinant amfibopeptide injection accepted

Zhitongcaijing · 10/14 13:57

Zhitong Finance App News, Li's Pharmaceutical Factory (00950) announced that on September 25, 2024, China's State Drug Administration accepted clinical trial applications for recombinant amfibopeptide injections, with acceptance numbers CXSL2400638 and CXSL2400639. This is the first clinical trial registration application for this product, and the submitted clinical plans include phase I (single dose and multiple doses) and phase II clinical plans.

Recombinant amphenotide injection is a type of therapeutic biological product discovered and owned by Zhaoke Pharmaceutical (Hefei) Co., Ltd., a wholly-owned subsidiary of the group, and complies with the pharmaceutical production quality control regulations issued by China's State Drug Administration.